Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Sarobe

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
When Cancer Vaccines Go ViralDavid Repáraz, Diana Llopiz, Pablo Sarobe
Medicina Clinica|July 11, 2006
[New therapies for hepatitis C]Lucía Gil-Guerrero, Pablo Sarobe, Jesús Prieto
Frontiers in Immunology|September 21, 2018
Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10Diana Llopiz, Marta Ruiz, Leyre Silva, et al.
Nature Reviews. Gastroenterology & Hepatology|April 14, 2021
Advances in immunotherapy for hepatocellular carcinomaBruno Sangro, Pablo Sarobe, Sandra Hervás-Stubbs, et al.
Human Vaccines & Immunotherapeutics|February 12, 2024
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapiesBelen Aparicio, Patrick Theunissen, Sandra Hervas-Stubbs, et al.
International Journal of Molecular Sciences|February 26, 2022
Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?David Repáraz, Belén Aparicio, Diana Llopiz, et al.
Seminars in Immunology|July 30, 2025
Epigenetic mechanisms in HCC immune landscape: Therapeutic implicationsMaite G Fernandez-Barrena, Iker Uriarte, Pablo Sarobe, et al.
Journal of Virology|January 23, 2009
Oncostatin M enhances the antiviral effects of type I interferon and activates immunostimulatory functions in liver epithelial cellsEsther Larrea, Rafael Aldabe, Iranzu Gonzalez, et al.
Molecular Immunology|December 13, 2006
Engineered promiscuous T helper peptides for the induction of immune responsesMarta Ruiz, Diana Llopiz, Aintzane Zabaleta, et al.
Cancer Immunology, Immunotherapy : CII|June 15, 2007
Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effectsDiana Llopiz, Javier Dotor, Aintzane Zabaleta, et al.
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
When Cancer Vaccines Go ViralDavid Repáraz, Diana Llopiz, Pablo Sarobe
Medicina Clinica|July 11, 2006
[New therapies for hepatitis C]Lucía Gil-Guerrero, Pablo Sarobe, Jesús Prieto
Frontiers in Immunology|September 21, 2018
Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10Diana Llopiz, Marta Ruiz, Leyre Silva, et al.
Nature Reviews. Gastroenterology & Hepatology|April 14, 2021
Advances in immunotherapy for hepatocellular carcinomaBruno Sangro, Pablo Sarobe, Sandra Hervás-Stubbs, et al.
Human Vaccines & Immunotherapeutics|February 12, 2024
Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapiesBelen Aparicio, Patrick Theunissen, Sandra Hervas-Stubbs, et al.
International Journal of Molecular Sciences|February 26, 2022
Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?David Repáraz, Belén Aparicio, Diana Llopiz, et al.
Seminars in Immunology|July 30, 2025
Epigenetic mechanisms in HCC immune landscape: Therapeutic implicationsMaite G Fernandez-Barrena, Iker Uriarte, Pablo Sarobe, et al.
Journal of Virology|January 23, 2009
Oncostatin M enhances the antiviral effects of type I interferon and activates immunostimulatory functions in liver epithelial cellsEsther Larrea, Rafael Aldabe, Iranzu Gonzalez, et al.
Molecular Immunology|December 13, 2006
Engineered promiscuous T helper peptides for the induction of immune responsesMarta Ruiz, Diana Llopiz, Aintzane Zabaleta, et al.
Cancer Immunology, Immunotherapy : CII|June 15, 2007
Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effectsDiana Llopiz, Javier Dotor, Aintzane Zabaleta, et al.
Pageof 9